BI drug named Promising Innovative Medicine in mesothelioma
FDA grants Breakthrough Therapy for Kisqali in premenopausal women.
Company successfully appealed against rejection last summer
The correlation between the upfront time to build and release a clinical database and its impact on downstream data management.
Is the UK’s NHS saving enough from the new wave of biosimilars?